Article record

接受以PCE为基础诱导化疗及同步放化疗的鼻咽癌患者肿瘤体积缩小与治疗结局之间的关联。

Association between tumor volume reduction and treatment outcomes in nasopharyngeal carcinoma treated with PCE-based induction chemotherapy and concurrent chemoradiotherapy.

临床研究鼻咽癌IF 3Q3

文献信息

PMID	42853545
原文	在 PubMed 查看原文 ↗
发表日期	2026
作者	Ya Guo 查看其他 14 位作者 Satoshi Saito；Kenji Makita；Tomohiro Enokida；Takashi Hiyama；Ryo Kuboki；Hirofumi Kuno；Masaki Nakamura；Yuichi Hiroshima；Hidenari Hirata；Masashi Wakabayashi；Yunhao Zhang；Nobukazu Tanaka；Makoto Tahara；Sadamoto Zenda
作者单位	Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. 查看其他 8 条单位信息 Department of Radiation Oncology, The Second Affiliated Hospital, Xi'an Jiao Tong University, Xi'an, China.；Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. kemaki3@east.ncc.go.jp.；Department of Radiation Oncology, NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan. kemaki3@east.ncc.go.jp.；Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. tenokida@east.ncc.go.jp.；Department of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan.；Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.；Division of Functional Imaging, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.；Biostatistics Division, Center for Research Administration and Support, National Cancer Center Japan Hospital East, Chiba, Japan.
期刊	International journal of clinical oncology
SCI 分区	Q3
IF	3
研究类型	临床研究 · 临床
所属专科	鼻咽癌

中文摘要

背景： 本研究旨在评估接受紫杉醇、卡铂和西妥昔单抗（PCE）为基础诱导化疗（IC）后行同步放化疗（CCRT）的局部区域晚期鼻咽癌（LA-NPC）患者中，总肿瘤体积缩小率（VRR）与治疗结局之间的关联。
方法： 纳入2017年9月至2024年12月期间计划接受IC-PCE后行CCRT的LA-NPC患者。计算总生存期（OS）和无进展生存期（PFS），并评估与PFS相关的因素。根据受试者工作特征曲线分析得出的截断值，将VRR二分类。
结果： 共纳入43例连续LA-NPC患者（中位年龄56岁）。中位随访时间为48个月（四分位距，34-69）。3年OS和PFS分别为95.3%和76.1%。共观察到12例PFS事件，包括局部区域复发（n=3）、远处转移（n=6）、两者兼有（n=1）和死亡（n=2）。在根据cStage（国际抗癌联盟第9版）调整的多变量分析中，高VRR（截断值，48.6%）被确定为与PFS改善显著相关的因素（风险比，0.21；95%置信区间，0.06-0.70；p=0.01）。
结论： VRR与PFS相关，提示IC-PCE后的肿瘤缩小可能作为预后标志物。

英文摘要

BACKGROUND: This study aimed to evaluate the association between total tumor volume reduction rate (VRR) and treatment outcomes in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) treated with paclitaxel, carboplatin, and cetuximab (PCE)-based induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT).
METHODS: Patients with LA-NPC who were planned to undergo IC-PCE followed by CCRT between September 2017 and December 2024 were included. Overall survival (OS) and progression-free survival (PFS) were calculated, and factors associated with PFS were evaluated. VRR was dichotomized based on a cutoff value derived from receiver operating characteristic curve analysis.
RESULTS: In total, 43 consecutive patients with LA-NPC (median age, 56 years) were included. The median follow-up time was 48 months (Interquartile Range, 34-69). The 3-year OS and PFS were 95.3% and 76.1%, respectively. A total of 12 PFS events were observed, including locoregional recurrence (n = 3), distant metastasis (n = 6), both (n = 1), and death (n = 2). In multivariable analysis adjusted for cStage (Union for International Cancer Control 9th edition), a high VRR (cutoff value, 48.6%) was identified as a significant factor associated with improved PFS (hazard ratio, 0.21; 95% confidence interval, 0.06-0.70; p = 0.01).
CONCLUSION: VRR was associated with PFS, suggesting that tumor shrinkage following IC-PCE may serve as a prognostic marker.